Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.

Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.

German medical science : GMS e-journal (2011-06-24)

Katrin Patrij, Marcel Reiser, Luise Wätzel, Hendrik Pels, Annika Kowoll, Ulrich Herrlinger, Andreas Engert, Michael Linnebank, Gabriele Schackert, Marlies Vogt-Schaden, Gerlinde Egerer, Monika Lamprecht, Tracy T Batchelor, Uwe Schlegel, Ingo G H Schmidt-Wolf

PMID21698087

ABSTRACT

We analyzed clinical outcome of patients with an isolated central nervous system lymphoma (CNSL) relapse after systemic non-Hodgkin's lymphoma (NHL). All 23 patients with an isolated secondary CNSL (SCNSL) treated at two institutions from 04/2003-12/2007 were included into this analysis. At cerebral relapse, 15/23 patients were treated with a regimen consisting of high-dose methotrexate (Bonn protocol). After a median follow-up of 6.5 months (range 1-68), 15/23 (65%) patients with SCNSL had relapsed or progressed. HD (high-dose)- methotrexate (MTX) chemotherapy according to the Bonn protocol is effective concerning response rates; however, overall survival of patients with SCNSL seems to be impaired in comparison to relapses in primary CNSL (PCNSL).

MATERIALI

N° Catalogo

Marchio

Descrizione del prodotto

V4890

Sigma-Aldrich

Vindesine sulfate salt hydrate, ≥95% (HPLC)